Just presented at 2024 AACR and used clinically on 15 patients
"Of the 13 evaluable patients, 11 experienced an objective response, with five complete responses and six partial responses). The other two evaluable patients had stable disease at the time of data analysis. Six patients experienced mild to moderate treatment-related adverse events, including fever, rigors, fatigue, diaphoresis, hematuria, urinary tract infection, acute urinary retention, and hepatic enzyme elevation."
If these data are correct, it's way more than showing promise! Even if the sample was relatively small, we are talking about low cost on location immune therapy for metastatic prostate cancer
aacr.org/about-the-aacr/new...
clinicaltrials.gov/study/NC... this is the trial